Core Insights - Pfizer Inc. generated over $85 billion from its COVID vaccine Comirnaty and over $20 billion from its antiviral Paxlovid between 2021 and 2023 [2] Group 1: Company Performance - Pfizer's COVID vaccine Comirnaty earned the company more than $85 billion from 2021 to 2023 [2] - The COVID antiviral Paxlovid contributed over $20 billion in revenue during the same period [2] Group 2: Analyst and Market Insights - The investing group Haggerston BioHealth provides insights for both novice and experienced biotech investors, including product sales forecasts and market analysis for major pharmaceutical companies [2]

Group 1 - The article discusses Neurocrine Biosciences (NASDAQ: NBIX) and highlights a previous analysis regarding a buying opportunity following a stock price drop related to schizophrenia data [2] - The author operates the Biotech Analysis Central service, which provides in-depth analysis of pharmaceutical companies and includes a library of over 600 biotech investing articles [2] - The service offers a model portfolio of more than 10 small and mid-cap stocks, along with live chat and various analysis and news reports to assist healthcare investors [2] Group 2 - The article does not contain any specific financial data or performance metrics related to Neurocrine Biosciences or the broader biotech industry [1][3][4]

This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33. ...

Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical ...

Group 1 - The article is authored by Terry Chrisomalis, who operates the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace, offering a two-week free trial for new subscribers [1] - Biotech Analysis Central provides a comprehensive library of over 600 biotech investing articles, a model portfolio of more than 10 small and mid-cap stocks, and various analysis and news reports to assist healthcare investors [2] - The service is priced at $49 per month, with a yearly plan available at a discounted rate of $399, reflecting a 33.50% discount [1] Group 2 - The article does not contain any stock, option, or derivative positions in the companies mentioned, nor does it plan to initiate any such positions within the next 72 hours [3] - Seeking Alpha clarifies that past performance does not guarantee future results and that no specific investment recommendations are provided [4]